Risk Mitigation for Oncology Clinical Trials

Life Sciences, Clinical Trials, Patient Recruitment & Retention,
  • Tuesday, May 18, 2021 | 1pm EDT (12pm CDT / 10am PDT)
  • 60 min

Since early 2020, the oncology clinical trials industry has made rapid changes in order to ensure mission-critical operations continue to protect participant rights, privacy, safety and data integrity. Particularly at clinical sites, research teams have had to restructure their staff and operations according to institutional directives to prevent the spread of COVID-19 while continuing to offer trial options to patients, with some regions more deeply affected than others.

In this webinar, Julie Martin, CEO & co-Owner of Scimega Research, will present on key areas of risk for US sponsors in critical oncology clinical trial operations in Canada and other geographic areas, and share mitigating tactics and strategies to build resiliency in 2021-2022 and maximize clinical development progress.

Register for this webinar to explore ways to ensure continuation of critical clinical trial operations through the pandemic and learn strategies for prevention of further delays, and how to achieve recovery and resiliency in 2021-2022. Specific topics to be discussed include:

  • Key risk areas of greatest concern in oncology clinical trials
  • Strategies used to mitigate threats in 2020 for small and mid-size US oncology biotechs: what worked and what didn’t
  • Cutting-edge small & mid-size oncology biotech trials: where to run them and which aspects may be different moving forward
  • What decision factors are expected to most influence your choice of region(s) in 2021-2022, including speed of start-up, participant diversity and regional participation rates

Bonus Offer: Register now and receive immediate access to the white paper Expert Guidance to Key Advantages of Canadian Regulatory Landscape.

Speaker

http://Julie%20Martin,%20Scimega

Julie Martin, CEO & co-Owner, Scimega

Julie joined Scimega 8 years ago. Having worked for 2 other CROs before, her passion for Scimega’s business and team stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most.

As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise & business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Julie is responsible for developing successful business strategies & leveraging industry opportunities, all of which support the common vision she shares with her team.

Her leadership & collaboration with the managing Board of Directors ensure the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

Message Presenter

Who Should Attend?

Clinical operations team leaders from small to mid-size biotech and biopharma companies managing complex oncology clinical studies will find the most benefit from this webinar. Relevant job titles include:

  • Manager/President/Director of Operations
  • Director Regulatory Affairs
  • CEO
  • CMO

What You Will Learn

In this webinar, participants will learn about:

  • Key risk areas of greatest concern in oncology clinical trials
  • Strategies used to mitigate threats in 2020 for small and mid-size US oncology biotechs: what worked and what didn’t
  • Cutting-edge small & mid-size oncology biotech trials: where to run them and which aspects may be different moving forward
  • What decision factors are expected to most influence your choice of region(s) in 2021-2022, including speed of start-up, participant diversity and regional participation rates

Xtalks Partner

Scimega

Scimega is a niche Canadian CRO skilled in collaborative vendor teaming with a proven track record of 23 years unparalleled Canadian oncology experience. Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. Offering an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of oncology experts go above-and-beyond for your study to provide:

✓ Identification and qualification of the right Canadian sites for your trial within just a few weeks thanks to our extensive network of Canadian Investigators.

✓ Site activation 50% faster than the industry average.

✓ In global oncology studies our Canadian sites frequently emerge among top enrollers. Like you, our clients develop cutting- edge oncology therapies, and they trust our results!

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account